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Abstract   
 
Introduction : Congenital and acquired heart diseases are highly prevalent in developing 
countries despite limited specialised care. Namibia established a paediatric cardiac service in 
2009 with significant human resource and infrastructural constraints. Therefore, patients are 
referred for cardiac interventions to South Africa. 
Objectives : To describe the diagnoses, clinical characteristics, interventions, post-operative 
morbidity and mortality and follow-up of patients referred for care.  
Methods:  Demographics, diagnoses, interventions, intra- and postoperative morbidity and 
mortality as well as longitudinal follow-up data of all patients referred to South Africa were 
recorded and analysed.  
Results: The total cohort constituted 193 patients of which 179 (93%) had congenital and 7% 
acquired heart disease. The majority of patients (78.8%) travelled more than 400 km to 
Windhoek prior to transfer. There were 28 percutaneous interventions. Palliative and 
definitive surgery was performed in 27 and 129 patients respectively. Eighty (80/156, 51.3%) 
patients had postoperative complications, of which 15 (9.6%) were a direct complication of 
surgery. Surgical mortality was 8/156 (5.1%, 95% confidence interval 1.2.2-9.8), with a 30-
day mortality of 3.2%. Prolonged ICU stay was associated with a 5% increased risk of death 
(Hazard Ratio 1.05, 95% confidence interval: 1.02-1.08, p=0.001). Follow-up was complete 
in 151 (78%) patients over seven years.  
Conclusions : Despite the challenges associated with a cardiac programme referring patients 
for intervention to a neighbouring country and the adverse characteristics of multiple lesions 
and complexity associated with late presentation, we report good surgical and interventional 
outcomes. Our goal remains to develop a comprehensive sustainable cardiac service in 
Namibia. 
 
 
Acknowledgements 
 
 
I would like to express my sincere thanks to the following: 
My supervisors for their guidance and wisdom throughout the study,  
My husband for his unending support and mentorship, 
Dr Susan Vosloo and Andre Brooks for the comprehensive reports that provided a big base for 
the study, and from which I drew so much work inspiration, 
And above all, the Almighty God for the gifts granted upon me. 
  
List of tables and figures 
 
 
Figure 1: Geographical distribution of referred patients. 
                                                       
Figure 2. Transcatheter interventions 
 
Figure 3: Cardiac Surgery cases by procedure 
 
Table 1. Primary diagnosis anatomical and physiological classification 
 
Table 2. Surgical risk stratification 
 
Table. 3 Patients not offered surgery 
 
Table 4. Postoperative complications 
 
Table 5. Mortality 
 
 
 
 
  
Abbreviations  
 
ARF Acute rheumatic fever 
ASAP Awareness Surveillance Advocacy Prevention 
CBMH Chris Barnard Memorial Hospital 
CCF Congestive cardiac failure 
CHD Congenital Heart Disease 
CI Confidence interval 
CRF Case report forms 
GAS Group A Streptococcus 
GDP Gross Domestic Product 
ICU Intensive Care Unit 
MDGs Millennium Development Goals 
MHSS   Ministry of Health and Social Services 
NCHP Namibia Children Heart Project 
PASCAR Pan African Society of Cardiology 
PPP Private Public Partnership 
RCWMCH Red Cross War Memorial Children’s Hospital 
REMEDY The Global Rheumatic Heart Disease Registry 
RHD Rheumatic Heart Disease 
RHDGen RHD Genetic Consortium 
SACH Save a Child’s Heart 
UN United Nations 
WHF World Heart Federation 
WHO World Health Organisation 
 
 
 
 
 
 
PART A: Manuscript 
 
 
South-South partnership to provide cardiac surgery: The 
Namibia Children Heart Project 
 
 
                                                          Fenny Fiindje Shidhika 
University of Cape Town student number: SHDFEN001 
  
                                                             Chapter 1 
1.1. Context 
Namibia is a sparsely populated country. There is currently no quantitative data to ascertain 
the high prevalence of congenital and acquired heart disease in the paediatric population. Due 
to the patients being referred with severe disease, Namibia has been funding for some 
patients to receive care in South Africa. However, sustainability is a major concern with this 
model in the face of declining governmental capital investment.. 
 
1.2. Ethical considerations 
The study was performed in accordance with ethical standards described in the Declaration of 
Helsinki, with ethical approval from institutional review boards at the University of Cape Town 
(HREC REF: 762/2016) and the Ministry of Health and Social Services in Namibia (REF: 
17/3/3). Parental consent had been obtained for surgery. We obtained a waiver of parental 
consent for this study. 
 
1.3. Author guidelines for the Cardiology in the Young journal 
Submission to Cardiology in the Young is exclusively via the web-based peer-review system, 
CTY Manuscript Central.  
Online submission enables rapid review and allows online manuscript tracking. Please use 
the following URL: http://mc.manuscriptcentral.com/cty  
Clinical Trials  
As a condition of consideration for publication, registration of clinical trials in a public trials 
registry is required. A clinical trial is defined by the International Committee of Medical 
Journal Editors (in accordance with the definition of the World Health Organisation) as any 
research project that prospectively assigns human participants or groups of humans to one or 
more health- related interventions to evaluate the effects on health outcomes. Trials must be 
registered before the start of patient enrolment. The registry must be accessible to the public 
at no charge. It must be open to all prospective registrants and managed by a not-for-profit 
organization. There must be a mechanism to ensure the validity of the registration data, and 
the registry should be electronically searchable. An acceptable registry must include at 
minimum a unique trial number, trial registration date, secondary identification information if 
assigned by sponsors or others, funding source(s), primary and secondary sponsor(s), 
responsible contact person, research contact person, official scientific title of the study, 
research ethics review, the medical condition being studied, intervention(s), key inclusion 
and exclusion criteria, study type, anticipated trial start date, target sample size, recruitment 
status, primary outcome, and key secondary outcomes. Registration information must be 
provided at the time of submission. Trial registry name, registration identification number, 
and the URL for the registry should be included at the end of the abstract.  
Manuscripts reporting the results of randomized controlled trials should include a 
“CONSORT” flow diagram to illustrate the progress of all patients in the study (See: Schulz 
KF, Altman D, for the CONSORT Group. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel group randomized trials. 
JAMA. 2001; 285(15): 1987–1991.) The flow diagram should be uploaded as a separate file 
to the manuscript.  
Editorial Policies  
Cardiology in the Young is devoted to cardiovascular issues affecting the young and the older 
patient with the sequels of cardiac disease acquired in childhood. Submission of both basic 
research and clinical papers is encouraged. Articles on fundamental principles will also be 
considered for publication. Reviews on recent developments are welcome. The Journal serves 
the interest of all professionals concerned with these topics. By design, the Journal is 
international and multidisciplinary in its approach, and the members of the Editorial Board 
take an active role in the Journal's mission. Prospective authors are encouraged to consult 
with the editors and members of the Editorial Board with any enquiries. The editors 
encourage the submission of articles from developing countries.  
Articles should be concerned with original research not published previously and not being 
considered for publication elsewhere. Submission of a manuscript to the Journal gives the 
publisher the right to publish that paper if it is accepted, and the copyright of the manuscript 
becomes property of the publisher. Manuscripts may be edited to improve clarity and 
expression.  
    
  
Authors must ensure that their studies comply with appropriate institutional and national 
guidelines for ethical matters. Specifically, by submission of a manuscript, the authors are 
responsible for compliance with guidelines and regulations of the authors' institution and all 
appropriate governmental agencies.  
Articles including human subjects must include a statement that informed consent was 
obtained and that the study was reviewed and approved by the institution's committee on 
human experimentation. Articles including animal experimentation must conform to the 
principles of the American Physiological Society, and a statement acknowledging 
conformation to these standards must be included in the Materials and methods section of the 
manuscript. Authors are also requested to identify possible conflicts of interest, especially if 
they relate to commercial sponsorship or equity holdings.  
Use of Abbreviations  
Abbreviations are not allowed in the text except for the following only: NYHA, CHD, MRI, 
CT, ICU and units of measure such as mmHg or kg, are allowed. However, any abbreviations 
can be used on tables and figures.  
Language  
The language of the Journal is English, but acceptance of a manuscript will reflect scientific 
rather than grammatical content. The editors undertake to facilitate the publication of papers 
from those authors whose native language is not English.  
Cambridge recommends that authors have their manuscripts checked by an English language 
native speaker before submission; this will ensure that submissions are judged at peer review 
exclusively on academic merit. We list a number of third-party services specialising in 
language editing and / or translation, and suggest that authors contact as appropriate. Use of 
any of these services is voluntary, and at the author's own expense. 
http://journals.cambridge.org/action/stream ? 
PageId=8728&level=2&menu=Authors&pageId= 3608  
Manuscripts  
Manuscripts should be submitted via the web-based peer-review system, CTY Manuscript 
Central and must include a complete set of Figures. Further information regarding Figure 
formats is outlined below.  
Authorship  
Authorship should be assumed only by those workers who have contributed materially to the 
work and its report, and who accept the responsibility for the accuracy of the concepts 
expressed. Colleagues who have otherwise assisted or collaborated should be recognized in 
the section for acknowledgements. An excellent guide to authorship is given by the Style 
Manual Committee of the Council of Biology Editors, and the editors encourage consultation 
with this source.  
  
  
Style  
The Journal uses the English language and as such does not use Latin terms such as ‘superior 
vena cava’. Anatomic terms should be given in the English language. Headlines and 
subheadings should be liberally employed in the methods, results, and discussion sections. 
Use short paragraphs whenever possible. The authors should strive for clarity of expression, 
avoiding, in particular, the use of jargon. Authors should also avoid conventions such as 
Group 1, Group 2, and so on, using descriptive titles rather than alphanumeric codes. Authors 
should use the definite/indefinite article where required.  
Title page  
The manuscript should include a title page, and it should follow these rules:  
1. Author qualifications (for example MD) must not be included on the authors’ list on the 
title page, except in the address for correspondence.  
2. Include the first names of the authors, followed by the initials of any middle names, and 
finally, the family name.  
3. Include the affiliation address (es) for the authors, to include the department, institute, city 
and country.  
4. Include an address for correspondence, with the full postal address, telephone and e-mail 
address of the author in question.  
Manuscript types  
Allowed manuscript types are Original Article, Article Commentaries, Brief Report, Review 
Article, Editorial, Image, Letter and Guidelines. Each is described below in detail.  
Original Articles  
Divide the manuscript into the following sections: o Title Page (see instructions on page 2) o 
Abstract o Keywords (3-6),  
o Headings: Introduction, Materials and methods, Results, Discussion, Acknowledgements, 
Financial Support, Conflicts of Interest, Ethical Standards, References, Tables, Figure 
legends and Figures  
Abbreviations  
Abbreviations are not allowed in the text except for the following only: NYHA, CHD, MRI, 
CT, ICU and units of measure such as mmHg or kg, are allowed. However, any abbreviations 
can be used on tables and figures.  
Abstract  
The Abstract should be no more than 250 words and should include statements identifying 
relevant methods and results justifying publication. Do not use abbreviations or symbols.  
Introduction  
The Introduction should be brief and set out the purposes for which the study has been 
performed. It should not include an extensive review of the literature.  
Materials and Methods  
The Materials and Methods should be sufficiently detailed so that readers and reviewers can 
understand precisely what has been done without studying the references directly. The 
description may be abbreviated when well-accepted techniques are used with appropriate 
reference to previously published methods. Statements confirming conformation to 
institutional and governmental review of the experimental protocol (see above in the Editorial 
policies section) should be included here.  
Results  
The results should be presented precisely. Reference to Tables and Figures, to the extent that 
they contribute substantively to help the reader understand clearly the relevant positive and 
negative findings, is encouraged. Keep discussion of their importance to a minimum in this 
section of the manuscript.  
Discussion  
The Discussion should relate directly to the study being reported. The Discussion should 
interpret the results, should describe the relevance of the results, and should include a 
discussion of the limitations of the study. Do not include a general review of the topic.  
Acknowledgements  
Acknowledgements should follow the discussion. Here you may acknowledge individuals or 
organisations that provided advice and/or support (non-financial). Formal financial support 
and funding should be listed in the following section. The Acknowledgements should be 
placed after the main body of the text before Financial Support. If there are no 
Acknowledgements, the title should be inserted followed by ‘‘None’’. Papers that do not 
include an Acknowledgements section will not be reviewed.  
Financial Support  
The Financial Support statement should be placed after the Acknowledgements and before 
the Conflicts of Interest section. Please provide details of the sources of financial support for 
all authors, including grant numbers. This is particularly important in the case of research that 
is supported by industry. Support from industry not only includes direct financial support for 
the study but also support in kind such as provision of medications, equipment, kits or 
reagents without charge or at reduced cost and provision of services such as statistical 
analysis. For example, ‘‘This work was supported by the Medical research Council (grant 
number XXXXXXX)’’. Multiple grant numbers should be separated by a comma and space, 
and where research was funded by more than one agency the different agencies should be 
separated by a semi-colon, with ‘‘and’’ before the final funder. Grants held by different 
authors should be identified as belonging to individual authors by the authors’ initials. For 
example, ‘‘This work was supported by the Wellcome Trust (A.B., grant numbers XXXX, 
YYYY), (C.D., grant number ZZZZ); the Natural Environment Research Council (E.F., grant 
number FFFF); and the National Institutes of Health (A.B., grant number GGGG), (E.F., 
grant number HHHH)’’. Where no specific funding has been provided for research, please 
provide the following statement: ‘‘This research received no specific grant from any funding 
agency, commercial or not-for-profit sectors.’’ Papers that do not include a Financial Support 
statement will not be reviewed.  
Conflicts of Interest  
The Conflicts of Interest section should be placed after Financial Support. Conflict of interest 
exists when an author has interests that might inappropriately influence his or her judgement, 
even if that judgement is not influenced. Because of this, authors must disclose potentially 
conflicting interests so that others can make judgements about such effects. At the time of 
submission authors should disclose any financial arrangements or connections they may have 
that are pertinent to the submitted manuscript and that may be perceived as potentially 
biasing their paper. Non-financial interests that could be relevant in this context should also 
be disclosed. If no relevant interests exist, this should be stated. This requirement applies to 
all the authors of a paper and to all categories of papers including letters to the editor. If there 
are no interests to declare, the title should be inserted followed by ‘‘None’’. Papers that do 
not include a Conflicts of Interest section will not be reviewed.  
Ethical Standards  
The Ethical Standards statement, if required, should be placed after the Conflict of Interest 
section before the References. Where research involves human and/or animal 
experimentation, the following statements should be included (as applicable): ‘‘The authors 
assert that all procedures contributing to this work comply with the ethical standards of the 
relevant national guidelines on human experimentation (please name) and with the Helsinki 
Declaration of 1975, as revised in 2008, and has been approved by the institutional  
committees (please name) .’’ and ‘‘The authors assert that all procedures contributing to this 
work comply with the ethical standards of the relevant national guides on the care and use of 
laboratory animals (please name) and has been approved by the institutional committee 
(please name).’’ If the research does not involve human and/or animal experimentation, this 
statement should be omitted. Papers reporting the results of human and/or animal 
experimentation that do not contain an Ethical Standards statement will not be reviewed. For 
more information on the ethical standards and procedures of Cambridge Journals, please visit 
Cambridge Journals Online.  
Article Commentaries  
Article Commentaries are responses to a previously published paper. The previously 
published paper must form the first reference of the Commentary. The authors of the 
previously published paper will be invited to respond, but further responses will not be 
accepted.  
Review Articles  
Reviews of recent developments are welcome. Authors are encouraged to contact the editor 
to determine the appropriateness for inclusion. The format is the same as for Original Articles 
(above). In particular, please see the note on Abbreviations, above.  
Case Reports / Brief Reports  
Case reports which add important new information will be published as Brief Reports, and 
must conform to the following requirements:  
o Abbreviations are not allowed in the text except for the following only: NYHA, CHD, 
MRI, CT, ICU and units of measure such as mmHg or kg, are allowed. However, any 
abbreviations can be used on tables and figures.  
 
o Headings before the References: Financial Support, Conflicts of Interest, Ethical Standards 
(Please see under Original Article above for the exact wording).  
o A title page (see instructions on page 2) o A maximum of three authors o An abstract (of 
about 60 words) o A maximum of 1,000 words  
o 3-6 key words o 2 Figures OR 2 Tables only o A maximum of 2 supplementary material 
files o A maximum of 10 references.  
Editorials and Letters to the Editor  
Readers are encouraged to write about any topic that relates to cardiology in the young. Such 
letters will appear in Letters to the Editor. They should be no longer than 500 words. Please 
include a title page (see instructions on page 2 above). Editorials are written on invitation 
but unsolicited articles of approximately 1,500 words which may have particular topical 
interest will be welcomed for consideration. Please include a title page (see instructions on 
page 2 above). For Editorials and Letters please also see the note on  
abbreviations under Images, below.  
Images in Congenital Cardiac Disease  
Definitive, unique, or extraordinary pictures of any aspect of congenital cardiac disease will 
be presented and must conform to the following requirements:  
• Abbreviations are not allowed in the text except for the following only: NYHA, CHD, 
MRI, CT, ICU and units of measure such as mmHg or kg, are allowed. However, any 
abbreviations can be used on tables and figures.  
• Headings before the References: Financial Support, Conflicts of Interest, Ethical Standards 
(Please see under Original Article above for the exact wording).  
• A title page (see instructions on page 2) A maximum of three authors, An abstract (of 
about 30 words) A maximum of 250 words 3-6 key words A maximum of 4 
images Only 1 reference. Instructional value and artistic merit will be considered in 
addition to scientific import and clinical relevance.  
Guidelines  
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                                                  Chapter 2 
2.1. Publication-ready manuscript 
 
A South-South partnership to provide cardiac surgery and interventions: The Namibian 
Children’s Heart Project.  
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Abstract 
Introduction : Congenital and acquired heart diseases are highly prevalent in developing 
countries despite limited specialised care. Namibia established a paediatric cardiac service in 
2009 with significant human resource and infrastructural constraints. Therefore, patients are 
referred for cardiac interventions to South Africa. 
Objectives : To describe the diagnoses, clinical characteristics, interventions, post-operative 
morbidity and mortality and follow-up of patients referred for care.  
Methods:  Demographics, diagnoses, interventions, intra- and postoperative morbidity and 
mortality as well as longitudinal follow-up data of all patients referred to South Africa were 
recorded and analysed.  
Results: The total cohort constituted 193 patients of which 179 (93%) had congenital and 7% 
acquired heart disease. The majority of patients (78.8%) travelled more than 400 km to 
Windhoek prior to transfer. There were 28 percutaneous interventions. Palliative and 
definitive surgery was performed in 27 and 129 patients respectively. Eighty (80/156, 51.3%) 
patients had postoperative complications, of which 15 (9.6%) were a direct complication of 
surgery. Surgical mortality was 8/156 (5.1%, 95% confidence interval 1.2.2-9.8), with a 30-
day mortality of 3.2%. Prolonged ICU stay was associated with a 5% increased risk of death 
(Hazard Ratio 1.05, 95% confidence interval: 1.02-1.08, p=0.001). Follow-up was complete 
in 151 (78%) patients over seven years.  
Conclusion : Despite the challenges associated with a cardiac programme referring patients 
for intervention to a neighbouring country and the adverse characteristics of multiple lesions 
and complexity associated with late presentation, we report good surgical and interventional 
outcomes. Our goal remains to develop a comprehensive sustainable cardiac service in 
Namibia. 
  
  
Introduction 
 
Congenital heart disease (CHD) is defined as the structural abnormalities of the heart or intra-
thoracic vessels present at birth that have actual or potential functional significance. CHD are 
the most common birth defects and are associated with significant morbidity and mortality 1, 2. 
Rheumatic heart disease is the sequel to acute rheumatic fever following Group A 
streptococcus infection and is the most common acquired heart disease in developing countries 
3. This combination results in a high burden of childhood heart diseases in Africa 4. Namibia 
gained independence from apartheid South Africa in 1990. It is a vast country (land area 824 
268 km2) with a sparse population of 2.3 million people 44% of whom are children 5. It is 
classified as an upper middle-income economy however, there is gross income inequality with 
a Gini co-efficient of 0,57 6. Before 2007, there was no paediatric cardiac service in Namibia. 
Outpatient paediatric cardiac clinics were started by a visiting volunteer paediatric cardiologist 
in Windhoek and with increasing government commitment, a catheterisation laboratory was 
commissioned in 2010 and a limited local surgical programme (catering mostly for adults and 
older children), was commenced. With significant human resource constraints - no paediatric 
intensive care specialists, no paediatric critical care nurses, no paediatric cardiac anaesthetists 
or paediatric cardiac surgeons and no paediatric intensive care, a centre for cardiac surgery for 
babies and small children (under 20 kg) has not been established. In response, in 2009 a public 
private partnership was brokered between the Christian Barnard Memorial Hospital in Cape 
Town, South Africa and the Namibian Ministry of Health and Social Services. Whilst the goal 
is to develop a fully functional and sustainable paediatric cardiac service in Namibia, in the 
interim patients have been referred to South Africa for surgery. This study describes the 
diagnoses, clinical characteristics, interventions, post-operative morbidity and mortality and 
the follow-up of patients referred to Cape Town between 2009 and 2015.  
 
Methods 
Study design and population 
We performed a retrospective data analysis of the 193 patients diagnosed with heart disease at 
Windhoek Central Hospital by a single paediatric cardiologist and referred to  Christian 
Barnard Memorial Hospital in Cape Town, South Africa from the period between 2009 and 
2015. Patient selection for surgery or intervention followed clinical and echocardiographic 
assessment and when relevant, cardiac catheterisation.  
 
Ethics 
The study was performed in accordance with ethical standards described in the Declaration of 
Helsinki, with ethical approval from institutional review boards at the University of Cape Town 
and the Ministry of Health and Social Services in Namibia. Parental consent had been obtained 
for surgery. We obtained a waiver of parental consent for this study. 
 
Data collection 
Data were captured from Windhoek Central Hospital and Christian Barnard Memorial Hospital 
registries using a standardised data collection form (Baseline Case Record Form – Appendix 
1) and recorded in Research Electronic Data Capture (REDCap) database. Dependent and 
independent variables included demographic profile, primary diagnosis co-morbid and pre-
operative data, echocardiography findings, cardiac catheterisation, surgery, post-operative 
morbidity and mortality and longitudinal follow-up outcomes. Patients were categorised using 
age and/or weight criteria and complexity estimated according to the presence of more than 
one lesion, associated pulmonary hypertension or complex CHD. The modified version of the 
hierarchy of heart defects developed by the CONgenital COR Vitia (CONCOR) registry was 
used for the primary diagnosis 7 and assigned codes according to the International 
Classification of Diseases and Related Health Problems 10th revision (ICD 10) coding system 
8. The Risk Adjustment for Congenital Heart Surgery (RACHS-1) model 9, 10 used here 
represents surgical complexity. Procedure nomenclature is assigned using the International 
Paediatric and Congenital Cardiac Code 11.  
 
Statistical analysis 
Data were analysed using STATA 14.  (StataCorp, 4905 Lakeway Dr, College Station, TX 
77845). Continuous variables were expressed as means with standard deviations or medians 
with interquartile ranges as appropriate. Categorical variables were expressed as absolute 
number frequencies and percentages. Linear regression models and Cox regression models 
were used to assess the relationship between and risk of appropriate variables with survival, 
respectively.  
 
Results 
Demographics  
One hundred ninety-three patients were referred to the Cape Town centre for cardiac care. 
Patients originated from all regions of Namibia (Figure 1). Distances to the referral centre 
ranged from 200 – 800 km with 107 people (55%) referred from villages over 700 km from 
Windhoek Central Hospital. The ratio of female to male was 1.3: 1.  The median age for 
presentation with congenital and acquired heart disease categories were 12 months 
(Interquartile range 5.0- 60.0) and 210 months (Interquartile range 180- 276 months) 
respectively. The median age at referral to Christiaan Barnard Memorial Hospital was 32.8 
months (Interquartile range 11.1-101.3).  
 
 
Figure 1: Geographical distribution of referred patients. 
(Green: referral centre, Orange: between 400-500 km, Red: further than 600 km) 
  
 
Baseline characteristics 
Primary diagnosis 
Congenital heart disease accounted for 179 (93 %) of patients. “Simple” left to right shunts 
were the largest group, n=77 (39.9%), 52 of which were ventricular septal defects. Partial and 
complete atrio-ventricular septal defects were found in 17 (8%) patients. complex cyanotic 
lesions, excluding tetralogy of Fallot, accounted for 29 (15%) patients. Obstructed left heart 
lesions were found in seven patients (see Table 1.)  Only 14 (7.3%) patients had acquired heart 
diseases (Rheumatic Heart Disease n=11 and Takayasu arteritis n=3). The predominant lesion 
in the Rheumatic Heart Disease group was mitral stenosis (n=8, 73%). One patient had isolated 
mitral regurgitation, one mixed mitral valve disease, one severe mitral and aortic regurgitation.  
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Table 1. Primary diagnosis anatomical and physiological 
classification 
                                                      Congenital heart disease 
Diagnosis    N=193   % 
                                                                   
Left to right shunts 
Partial AVSD (7)    3,6% 
Complete AVSD (6)     3,1% 
VSD (52)   26,9% 
ASD (8)     4,1% 
PDA (15)   7,7% 
                                                          
Obstructive right heart lesions 
Tetralogy of Fallot spectrum 
Classic 20 
Pulmonary atresia 7 
DORV-Tetralogy 6 
(33)  17.1% 
Isolated pulmonary valvar stenosis (9)   4.7% 
Double Chambered RV (2)   1.0% 
                                                           
Obstructive left heart lesions 
Interrupted Aortic Arch (2)    1.0% 
Coarctation of Aorta (3)    1.6% 
Aortic stenosis 
Valvar 3 
Sub- and supravalvar 1 
(4)    2.1% 
                                                   
Atrio-ventricular and ventriculo-arterial discordance 
TGA (simple) (2)  1.0% 
ccTGA (1)   0.5% 
Ventricular inversion (1)   0.5% 
DORV  
Taussig-Bing 1 
Non-committed VSD 1 
(2)   1.0% 
Pulmonary atresia/IVS (1)   0.5% 
                                                     
Pulmonary vein abnormalities 
TAPVD (1)   0.5% 
Isolated pulmonary vein stenosis (1)   0.5% 
                                                     
Single ventricle physiology 
Tricuspid atresia (9)   4.7% 
Unbalanced AVSD 
Isolated 1 
Unbalanced AVSD-Tetralogy 2 
(3)  1.6% 
DILV (3)  1.6% 
HLH complex (1)   0.5% 
 
                                                        Acquired heart disease 
Rheumatic heart disease (11) 5.7% 
Takayasu arteritis (3)   1.6% 
 
 
Abbreviations: 
AVSD: Atrio-ventricular Septal Defect, VSD; Ventricular Septa; Defect, ASD; Atrial Septal 
Defect, PDA; Patent Ductus Arteriosus, TGA; Transposition of the Great Arteries, CCTGA- 
Congenitally Corrected Transposition of the Great Arteries, DORV; Double Outlet Right 
Ventricle, RV; Right Ventricle, IVS: Intact Ventricular Septum, TAPVD; Total Anomalous 
Pulmonary Venous Drainage, DILV; Double Inlet Left Ventricle, HLH; Hypoplastic Left Heart  
 
 
Comorbidity 
The number of patients with Trisomy 21 was 13 (6.7%). The 22q11.3 microdeletion was 
isolated in five patients (2.6%) but not all patients with CHD were screened for this gene 
defect. Heterotaxy was discovered in four (2.1%), Noonan’s syndrome was diagnosed in two 
patients (1,0%); Congenital diaphragmatic hernia in three patients (1.6%) and one patient had 
the VACTERL (Vertebral defects, Anal atresia, Cardiac defects, Tracheoesophageal fistula, 
Renal anomalies and Limb abnormalities) association. Significant failure to thrive (poor 
somatic growth equal to or greater than three standard deviations below the mean for age and 
height) was found in 76 patients (39.4%). In our cohort, 80 (41.5%) had clinical features and 
echocardiographic evidence of pulmonary hypertension. Almost three-quarters of the patients 
had a delay to surgery due to an existing respiratory infection. Two patients were on 
respiratory support before surgery. There were two patients in the last trimester of pregnancy 
referred for percutaneous transcatheter mitral valve commissurotomy for RHD associated 
mitral valve stenosis. 
 
Catheterisation 
Diagnostic cardiac catheterisation 
Cardiac catheterisation was performed in 89 patients (46.1%). The majority 62 (69.7%) were 
diagnostic/haemodynamic studies. Median age at catheterisation was 70.1 months 
(Interquartile range: 17.6 – 155.4). Catheterisation was performed in 30 (33.7%) patients with 
severe pulmonary hypertension to assess suitability for surgery. Of this group, three patients 
proved to have irreversible pulmonary hypertension secondary to pulmonary vascular disease 
and deemed inoperable. Catheterisation was done as routine inter-stage assessment in those 
undergoing staged single ventricle palliation or to delineate anatomy for biventricular repair in 
32 (36,0%). 
 
Transcatheter interventions 
There were 28 (30.3%) transcatheter interventions (on 27 patients) including eight 
percutaneous mitral transcatheter commissurotomies and two radio-frequency ablations (see 
Figure 2). The remainder were for CHD interventions. There was one complication where an 
Amplatzer Patent Ductus Arteriosus occluder device (ADO 1) embolised into the left 
pulmonary artery. The device was removed, and the duct ligated surgically.  
 
 
 
Figure 2. Transcatheter interventions 
 
Surgery 
The median age at presentation to Windhoek Central Hospital was 12 months (Interquartile 
range 5.0 - 47.5) however, the median age at time of surgery was 28.4 months (Interquartile 
range: 11.1-78.0). In total, 156 cases were performed; surgery was elective in 142/156 (91.0%) 
cases. Twenty-seven (17.3%) of all patients who underwent surgery had palliative procedures. 
Of these, 11 were for single ventricle palliation (10 Glenn shunts and one total cavopulmonary 
connection). Six patients had a right modified Blalock-Taussig shunt, nine had pulmonary 
artery bandings and one had a central shunt. One hundred twenty-nine (82.7%) patients had a 
full repair with 15 of these (11.6%) performed off cardiopulmonary bypass (See Figure 2). 
Those classified as “other” included three patients with double outlet right ventricle, five 
patients undergoing right ventricular outflow tract reconstruction and/or pulmonary valve 
replacement, two patients with divided right ventricle and ventricular septal defect repair and 
one each of left atrio-ventricular valve repair, tricuspid valve repair, divided right ventricle, 
ventricular septal defect and Sinus of Valsalva repair and ventricular septal defect /aortic valve 
repair. Risk stratification for surgical procedures (RACHS-1 categories) is illustrated in Table 
2.  
There were 11 re-operations (7.0%); four for haemodynamically significant residual defects, 
two in a child with pulmonary atresia, one with excessive pulmonary blood flow after systemic 
to pulmonary shunt, one with persistent ascites after right ventricular outflow tract 
reconstruction in tetralogy of Fallot (with hypoplastic branches) and one for a residual 
ventricular septal defect after atrio-ventricular septal defect repair. two patients needed 
emergency revision; one for refractory bleeding and the other for systemic to pulmonary shunt 
thrombosis. 
 Two babies with congenital diaphragmatic hernia and one with tracheoesophageal fistula 
had those lesions repaired before cardiac surgery. Twelve patients with CHD were not offered 
surgery (Table 3). 
 
Table.2 Surgical risk classification 
 
RACHS-1 Category Score Absolute frequency Percentage 
1 21 13.6 
2 68 43.6 
3 58 37.1 
4 9 5.7 
Total 156 100.00 
 
 
 
 
 
Figure 3: Cardiac Surgery cases by procedure 
 
Abbreviations: VSD: Ventricular Septal Defect, TOF: Tetralogy of Fallot, PDA: Patent 
Ductus Arteriosus, AVSD: Atrio-ventricular septal defect, ASD: Atrial Septal Defect, CoA: 
Coarctation of the Aorta, MVR: Mitral valve replacement, AVR: Aortic Valve replacement, 
IAA: Interrupted aortic arch. 
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Table. 3 Patients not offered surgery 
 
 Ag
e 
Diagnosis Investigation Conclusion Outcome  
1 9y Left isomerism  
Interrupted aortic 
arch, 
AVSD (common 
atrium)  
Left AV valve 
incompetence 
LV non-compaction 
Cardiac 
catheterisation: 
PVRi 10 WU 
Anatomy and 
haemodynamics not 
suitable for surgery 
Unknown* 
2 1m AVSD  
Diaphragmatic 
hernia 
Trisomy 21  
Cardiac 
catheterisation: 
PVRi 6 WU,  
Poor respiratory capacity 
Advance pulmonary 
vascular disease 
Eisenmenger 
syndrome 
4 9m Transposition of 
great arteries, 
Ventricular septal 
defect 
Cardiac 
catheterisation 
PVRi > 6 WU 
Irreversible pulmonary 
vascular disease,  
Deceased 
5 10
m 
Complete AVSD  
PDA 
Cardiac 
catheterisation: 
PVRi 12 WU 
Irreversible pulmonary 
vascular disease,  
Unknown* 
6 3m Shone syndrome  
Sub-aortic stenosis  
Coarctation of aorta 
ASD, VSD 
Cardiac 
catheterisation 
Anatomy and 
haemodynamics not 
suitable for surgery 
Unknown* 
7 11
y 
Muscular VSD  
PDA 
Echocardiogram Haemodynamically 
insignificant 
Alive 
8 5m Situs ambiguous  
Discordant AV 
connections 
Interrupted IVC 
VSD 
Cardiac 
catheterisation 
Complex and not suitable 
for surgery 
Alive 
9 3m Tetralogy of Fallot 
with 
Pulmonary atresia 
and MAPCAS 
Pulmonary artery 
hypoplasia  
Catheterisation Inadequate pulmonary 
arteries not suitable for 
surgery 
Unknown* 
10 3d Shone complex 
Interrupted aortic 
arch 
Sub-aortic stenosis  
Catheterisation Anatomy unsuitable for 
surgery 
Unknown* 
Aorto-pulmonary 
window ASD, VSD 
11 15
y 
Double inlet left 
ventricle 
AV valve 
regurgitation  
Previous Coarctation 
repair, Bi-directional 
Glenn shunt 
TOE and 
catheterisation 
Not suitable for 
univentricular palliation 
Unknown* 
12 1w Pulmonary vein 
stenosis  
Severe pulmonary 
venous hypertension 
Echocardiogram Anatomy not suitable for 
correction 
Unknown* 
 
 
*Lost to follow-up 
 
Abbreviations: AVSD: Atrio-ventricular septal defect, AV: Atrio-ventricular, LV: Left 
Ventricle, PDA: Patent Ductus Arteriosus, ASD: Atrial Septal Defect, VSD: Ventricular 
Septal Defect, AV: Atrio-ventricular, IVC: Inferior Vena Cava, PVRi: Pulmonary Venous 
Resistance indexed, WU: Woods Units 
 
Outcome 
Morbidity 
Intra-operative morbidity 
One intra-operative complication was documented. This patient sustained left coronary injury 
during a single ventricle palliation with bilateral pulmonary artery augmentation. The coronary 
artery was repaired with successful re-vascularisation. 
 
Postoperative morbidity 
Eighty (80/156, 51.3%) patients had postoperative complications, of which 15 (9.6%) were a 
direct complication of cardiac surgery (Table 4). The median post-operative stay in intensive 
care was 5 days (Inter-quartile range: 3 - 7) with the maximum 106 days. Prolonged ICU stay, 
defined as 5 days after surgery, occurred in n=81 (51.9%). 
  
 
 
Table 4. Postoperative complications 
 
Complication Frequency % n=156 
Pneumonia 41 26,28 
Arrhythmia (tachyarrhythmia, AV dissociation)  9 5,77 
Pulmonary hypertensive crisis  9 5,77 
Persistent pleural drainage (transudate)  6 3,85 
Pericardiotomy syndrome  4 2,56 
Bleeding 2 1,28 
Diaphragm paralysis  2 1,28 
Pulmonary reperfusion injury  2 1,28 
Wound sepsis 2 1,28 
Myocardial ischaemia 1 0,64 
Persistent pulmonary drainage (chylothorax)  1 0,64 
Systemic to pulmonary shunt thrombosis 1 0,64 
   
Total 80 51,28 
 
Mortality 
In total, there were eight surgical deaths with an overall mortality of 4.2%. Five of these were 
early (< 28 days) and three late deaths (Refer to Table 5). Two deaths occurred within 24-48 
hours of surgery, two on day five and one each on days 20, 50 and 90, respectively. The 30-
day mortality rate was 3.8 [95% Confidence interval 1.4-8.2]. Median age at death was 7.3 
months (Interquartile range: 6.2-22.5).  
  
 
Table 5: Mortality 
 Age  Diagnoses RACHS 
score 
IPCCC 
procedures 
Death Cause of death 
1 13m Complete AVSD, PDA 
Trisomy 21 
3 PA Band and  
PDA ligation 
Early  Traumatic  
pericardiocentesis 
2 6m Pulmonary infundibular 
and valvar stenosis 
Dysplastic tricuspid 
valve 
2 RVOTO relief 
with creation ASD 
Early Restrictive right  
ventricle and 
tachyarrhythmia 
3 20m Tetralogy of Fallot 2 Tetralogy repair 
and reoperation 
Early Restrictive right  
ventricle and  
tachyarrhythmia 
4 11y DORV with Tetralogy 
and MAPCAs 
3 Bidirectional 
Glenn,  
atrial septectomy, 
PA Band, repair 
LAD 
Early Myocardial 
Infarction 
5 20m Complete unbalanced 
AVSD and pulmonary 
stenosis 
3 RMBTS Early Unknown 
6 3m TGA with VSD 
VACTERL association 
Tracheoesophageal 
fistula  
3 PA Band, PDA 
ligation, repair 
TOF 
Late Respiratory 
failure chronic 
lung disease 
7 6m Severe infundibular and 
valvar pulmonary 
stenosis 
2 RVOT obstruction 
patch and creation 
ASD 
Early Restrictive right  
ventricle and 
tachyarrhythmia 
8 8m Complete unbalanced 
AVSD Right AV valve 
atresia, severe Left AV 
valve regurgitation 
3 Left AV valve 
repair not suitable 
for bi-ventricular 
repair 
Early Cardiorespiratory 
failure 
 
Abbreviations: AVSD: Atrio-ventricular septal defect, PDA: Patent Ductus Arteriosus, 
DORV: Double Outlet Right Ventricle, MAPCAs: Medium-sized Arterio-Pulmonary 
Collateral Arteries, TGA: Transposition of the Great Arteries, AV: Atrio-ventricular, 
RVOTO: Right ventricular outflow tract obstruction, ASD: Atrial Septal Defect, PA: 
Pulmonary artery, LAD: left anterior descending artery, TOF: Tetralogy of Fallot. 
 
 
 
Longitudinal follow-up rates and overall survival 
Forty-two patients (21.8%) were lost to follow-up (failed to attend a scheduled visit for 24 
months from the last visit) over the period 1 December 2009 to 31 December 2016. 
 
DISCUSSION 
 
The major findings of this study from Africa are that despite the distance to the referral centre 
(more than half of all patients referred for cardiac surgery and intervention reside more than 
700 km from the only referral centre in Namibia) and their late presentation and referral, 
surgical therapy could be offered to the patients with good outcomes with an acceptable overall 
mortality of 4.2 % despite complex disease, significant co-morbidity and protracted post-
operative intensive care. A high number of these patients, 21.8%, are lost to follow-up within 
24 months. 
Distance to care 
In poor countries, long distances to care represent an additional access challenge. The majority 
of our patients live in the northern regions of Namibia in mostly rural, agrarian communities 
surviving through subsistence farming. If they are recognised as having cardiac disease, they 
are sent to the regional centre for paediatric services at the Oshakati Intermediate Hospital. 
This hospital is located in excess of 700 km from the national referral centre in Windhoek.  The 
Ministry of health and Social Services patient transport between Oshakati and Windhoek takes 
place by road once a week. Emergencies are transported by an air ambulance after lengthy 
procedural delays and at substantial extra direct cost. Poverty, distance to care and poor 
transport infrastructure represent significant barriers to all levels of health care and of course 
to responsible follow-up. Recognising these barriers to care, regular outreach visits to the north 
of Namibia were instituted in 2013 to provide patient care and upgrade local knowledge and 
cardiology skills.  
 
Late diagnosis and referral, complex disease and significant co-morbidity.  
The late presentation of patients with CHD to specialist care is primarily a consequence of poor 
early diagnosis and late recognition. This reflects poor knowledge of CHD in the peripheral 
referral regions of the country and the low penetrance of specialist paediatric services through 
the health system. Late detection has two significant results. Firstly, that those patients with 
critical congenital heart disease (20% of all CHD) 12 who should have early surgery are never 
detected and die without treatment. The low numbers of babies with, for example, transposition 
of the great arteries or anomalous pulmonary venous connection in this cohort can be 
understood in this context. Secondly, by the time patients are diagnosed they have severe 
complications of their underlying disease. Pulmonary vascular disease secondary to severe 
pulmonary hypertension is the most common example and despite the pre-selection of patients 
by the cardiologist in Windhoek, a further three patients with pulmonary hypertension were 
deemed inoperable in Cape Town. The review does not reflect those many patients denied 
referral from Windhoek due to established pulmonary vascular disease. The problems posed 
by pulmonary hypertension are further reflected in the nine patients with post-operative 
pulmonary hypertensive crises. The higher age at presentation in the CHD group is also the 
reason for the high number of diagnostic cardiac catheterisations performed to assess the 
reversibility of pulmonary hypertension prior to surgery. Whilst failure to thrive is often multi-
factorial, especially in countries with high levels of unemployment, poverty and malnutrition, 
the high numbers with failure to thrive in the CHD cohort reflects the severity of their disease 
and a period of almost 22 months between presentation and referral for assessment. Pre-
existing respiratory infection is a known risk factor for cardiac surgery 13. A high number of 
children arrived for surgery with pre-existing respiratory disease, had in-hospital delay to 
operation and lengthy post-operative recovery.  
 
The case-mix is diverse, predominantly CHD and predictable. The number of patients with 
Rheumatic Heart Disease (13) was low which does not reflect the high prevalence of this 
preventable disease in Namibia 14, 15. Cardiac surgery was started at the Windhoek Central 
Hospital in October 2010 and through a similar period, most patients with Rheumatic Heart 
Disease needing valve surgery (200 reported cases) 16 had surgery at Windhoek Central 
Hospital.  Those with rheumatic heart disease sent to Cape Town included children with body 
mass under 20kg and 8 patients needing percutaneous transcatheter mitral valve 
commissurotomy for mitral stenosis when the technology (Inoue percutaneous transcatheter 
mitral valve commissurotomy catheter) was not available at Windhoek Central Hospital.  
 
Surgical mortality and length of Intensive Care 
The low surgical mortality compares favourably with similar programs in developing countries 
and international standards established by the Society of Cardiothoracic Surgeons 17-20. The 
likely causes of the post-operative deaths are revealing and suggest that in three patients the 
risk associated with restrictive right ventricular pathophysiology was not fully appreciated pre-
operatively. Two patients with complex atrio-ventricular septal defects also had abnormal right 
ventricle pathology. Pre-operative pulmonary hypertension was neither associated with 
mortality or length of time in ICU suggesting appropriate pre-selection. The length of post-
operative intensive care correlates with mortality. Preoperative respiratory infection was 
common (75%) but neither this nor failure to thrive was a risk factor for death even though 
both factors were associated with the prolonged ICU stay after operation.  
 
Loss to follow-up and after-care 
Post-operative care and surveillance is a determinant of long-term outcome. The outreach paediatric 
cardiology service to the north of the country was started in 2013 partly to address this challenge. 
Although it has improved, patient “connection” with primary health facilities and with specialist 
cardiac care is poor. The lengthy distances to the referral centres, poor transport infrastructure and 
the fact that many of our families live in abject poverty further contribute to the problem. Many 
families simply cannot afford private transport to the hospitals or primary care services to sustain their 
follow-up care. There is no electronic medical record and no national database for patients within the 
system, so case finding and patient tracking remain problematic.  Despite the health service 
challenges, the combination of a patient registry, outreach programme and the continuity of care 
provided by a single cardiologist have contributed to 80% of patients remaining within follow-up 
(which compares favourably with reports from elsewhere in Africa) 15, 21.  However, the loss to follow-
up rate of 20% is still high and suggests that our mortality statistics underestimate late post-operative 
deaths.  
Implications for health policy, practice and research 
The Namibian Children’s Heart Project is a humanitarian programme aimed to provide cardiac 
surgery and intervention for indigent Namibians who are unable to access such services in 
Namibia. It is South-South collaboration and a unique funding model on the African continent 
with national government purchasing services from private sector providers in a neighbouring 
country. Although the Namibian Children’s Heart Project has up to December 2015 brought 
relief to almost 200 patients with satisfactory results, these patients should be able to get the 
care they require in Namibia. There is an overwhelming general agreement evidence that the 
birth prevalence of CHD is 8 per 1000 live births 2, 22.  Applying this to Namibia, with annual 
births per annum of 60 000, 23 there are 480 babies born every year with CHD. Of these 40% 
will need heart surgery and 20% who have critical CHD, require it in infancy 1, 12, 24 Without 
addressing the backlog, 200 patients over six years is not enough, and the Ministry of health 
and Social Services should be planning heart surgery for at least 200 patients per year in the 
country.  
It is our objective to develop a comprehensive, sustainable and self-sufficient paediatric cardiac 
surgical service in Namibia. The challenges are both human resources based and 
infrastructural. The minimum specialist requirements are a paediatric cardiac surgeon with 
sufficient training and recognised expertise in CHD, anaesthetists trained in paediatric cardiac 
care, a paediatric intensive care specialist and a well-trained cadre of paediatric cardiac 
intensive care nurses.  In a country without a paediatric intensive care, construction of such a 
facility is a priority. Only with this facility, appropriate financial resources from government 
for heart surgery in children and a collective and cooperative effort to upgrade nurse ICU skills 
for babies and children will we be able to offer safe surgery within Namibia. Implementation 
requires strict adherence to established quality improvement protocols, with proposed 
participation in the International Quality Improvement Collaborative 9, 17.  
 
Recommendations 
1. Continuous capacity building at all levels is mandatory. 
 
2. Diagnostic services within the health department need to improve as without this, the 
sick newborn with critical CHD will remain invisible 25 26. 
 
3. The National Ministerial Outreach programme should be expanded at intermediate 
hospitals across the country.  
 
4. Pulse oximetry screening should be considered in neonatal units to improve detection 
yields. 
 
5. We strongly recommend a national database of heart disease in children.  
  
6. Follow-up rates will be improved by calling the patients when they miss their scheduled 
appointments. Most families own cellular phones however the challenge is that patients 
are constantly changing their contact numbers and for those residing in remote areas, 
connectivity might be poor.  
  
Conclusion 
We have demonstrated an effective model for humanitarian care through a South-South 
collaboration, which has achieved satisfactory outcomes for those fortunate to be referred and 
funded by government. Despite health services constraints, adverse characteristics of multiple 
lesions and complexity associated with late presentation, the 30-day mortality rate is only 3.2%. 
The cohort reports only those who travelled to Cape Town and does not address the challenge 
of the many patients who were referred but died or became inoperable, whilst waiting. This 
study highlights health service deficiencies needing improvement and a commitment from the 
team to achieve safe surgery for babies and children within a sustainable national programme 
in Namibia.  
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Addendum 2: Baseline CRF 
APPENDIX 1 
The Namibia children heart project; a 6-year retrospective review 
DATA COLLECTION FORM 
 
1.  DEMOGRAPHICS 
Subject ID Number: (Sequential number plus patient initials):   ____________ 
 
Geographical Region: 
 Erongo
 Hardap
 Kavango 
 Khomas
 Ohangwena
 Omaheke
 Oshana
 Oshikoto
 Otjozondjupa
	  Zambezi
 
Date of birth (DD /MM /YYYY):     ______________ (DD/MM/YYYY) 
Date of initial presentation at Windhoek facility:  ______________ (DD/MM/YYYY) 
 
Age at presentation (auto-calculated):               ______________ (MONTHS) 
 
Cape Town facility Admission date:    ______________ (DD/MM/YYYY) 
Cape Town facility Discharge date:    ______________ (DD/MM/YYYY) 
 
Age at admission to Cape Town facility (auto-calculated): _____________ (MONTHS) 
 
Sex: 
1. M  
2. F 
3. Other/Missing 
 
   
 
2. DIAGNOSIS (According to the ICD.10 coding system Appendix 2.) 
 
Primary Cardiac Dx Code:   ______________ (xxx.xx) 
 
Type of Heart Disease 
1. Acquired 
1. Takayasu’s Arteritis 
2. Rheumatic Heart Disease 
 
2. Congenital 
1. Coarctation of Aorta 
2. Interrupted Aortic Arch 
3. Sub-aortic Stenosis 
4. Valvar Aortic stenosis 
5. Tricuspid Atresia 
6. Double Inlet Left Ventricle 
7. Double Outlet Right 
Ventricle 
8. Mitral Stenosis 
9. Double Orifice Mitral Valve 
10. Mitral Valve Prolapse 
11. Other. Pls describe 
______________________ 
Additional lesions: 
1. None 
2. Total Anomalous Pulmonary Venous Drainage 
3. Partial Anomalous Pulmonary Venous Drainage 
4. Atrio-ventricular Disconcordance 
5. Ventriculo-arterial Disconcordance 
6. Isomeric atrial appendages 
7. Other: Please describe__________________ 
 
Other relevant diagnoses: 
 
Diagnosis 2:  ______________ (xxx.xx) 
Diagnosis 3:  ______________ (xxx.xx) 
Diagnosis 4: ______________ (xxx.xx) 
Diagnosis 5: ______________ (xxx.xx) 
Diagnosis 6: ______________ (xxx.xx) 
Other/Missing: ______________ (999) 
 
Co-morbidities /Associations/Syndromes 
1. HIV 
2. Diaphragmatic hernia 
3. Down syndrome 
4. Noonan’s syndrome 
5. Shone Complex 
6. Pulmonary TB 
7. Congenital Rubella 
8. George’s Syndrome 
9. Isolated midline defects 
10. Skeletal abnormalities (e.g. 
kyphosis, scoliosis, radial) 
11. VACTERL association 
12. Congenital renal abnormalities 
13. Other: Please 
describe__________________ 
 
 
 
Pregnant at time of intervention?  
1. Yes 
If yes, gestational age:  _______________ (weeks)  
2. No 
3. Unknown/Missing 
 
RACHS Category score: 

☐1.  ☐2.  ☐3.  ☐4.  ☐5.  ☐6. 
 
Was patient returned to WCH because of contraindications for surgery? 
1. Yes 
2. No 
3. Other 
 
If yes, please describe the nature of the contraindication 
 
________________________________________________ 
 
Outcome: 
1. Patient was readmitted for intervention at a later date (within the review period) 
2. Patient was deemed as an inappropriate candidate for surgery with no plans for 
further intervention 
 
 
 
 
3. CATHETERISATION 
1. Yes 
2. No. If no, please proceed to Section.4 below. 
 
If yes, 
Date of catheterization:   __________________ (MM/ DD /YYYY) 
Age at catheterization:   ___________________ (MONTHS)  
 
Primary Indication for catheterization (tick one of the below): 
1. Diagnostic     
2. Haemodynamic   
3. Interventional   
 
If Diagnostic, please complete this section 
 
1. Outcome 
1. Not amenable to surgery or other intervention 
1. Complex and inoperable anatomy 
2. Irreversible PHT 
2. Found to be suitable candidate for surgery 
3. Found to be suitable candidate for interventional catheterization 
4. Other. Please describe. --------------------- 
 
2. Catheterization Complications? 
1. Yes  
2. No 
 
3. If yes, (can indicate more than one)   
1. Arrhythmia 
2. Bleeding 
3. Cardiac arrest 
4. Pulmonary hypertensive 
crisis 
5. Death 
6. Other/Missing 
 
If Haemodynamic, please complete this section 
Outcome 
1. Irreversible pulmonary obstructive vascular disease 
2. Reversible pulmonary obstructive vascular disease 
3. Other. Please describe. --------------------- 
 
Baseline Pulmonary vascular resistance index: ___________ (xx.xx) 
Post O2 administration pulmonary vascular resistance index: ______ (xx.xx) 
 
Catheterization Complications? 
1. Yes  
2. No 
3. Unknown/Missing 
If yes, (can indicate more than one)   
1. Arrhythmia 
2. Bleeding 
3. Cardiac arrest 
4. Death 
5. Pulmonary 
hypertensive crisis 
6. Other/Missing 
 
If Interventional, please complete this section 
Outcome  
1. ASD device closure  
Successful?  
1.  Yes            2. No 
 
2. PDA device closure  
Successful?  
1.  Yes            2. No 
 
3. Aortic stenting  
Successful?  
1. Yes           2. No 
Site of stenting:  __________________ (text) 
 
4. RVOT/branch pulmonary arteries stenting  
Successful?  
1. Yes          2. No 
5. Percutaneous mitral valvuloplasty  
Successful? 
1. Yes          2. No 
3. Initial mean gradient:   _____ mmHg 
4. Post valvuloplasty mean gradient:  _____mmHg 
 
6. Percutaneous mitral valvuloplasty 
Successful? 
1. Yes          2. No 
Initial mean gradient:   _____mmHg 
Post valvuloplasty mean gradient:  _____mmHg 
 
 
 
7. Radiofrequency ablation 
Successful? 
1. Yes          2. No 
 
8. Other. Pls describe:  __________________________________ 
Successful? 
1. Yes          2. No 
 
Catheterization Complications? 
1. Yes          2. No 
 
If yes, (can indicate more than one)   
1. Arrhythmia 
2. Bleeding 
3. Cardiac arrest 
4. Death 
5. Pulmonary hypertensive crisis 
6. Other/Missing 
 
4. SURGERY 
1. Yes 
2. No 
If no, why not?  
1. Deemed inoperable 
2. Advanced pulmonary obstructive vascular disease 
3. Complex anatomy  
4. Unknown/Missing 
 
If no, proceed to next section. 
If yes, 
Date of Surgery:      ______________ (DD/MM/YYYY) 
Type:  
1. Elective 
2. Emergency 
3. Re-operation   
If re-operation, date of previous surgery:  ______________ (DD/MM/YYYY) 
 
Palliative surgery?  
1. Yes  
2. No 
If yes, 
1. Central shunt 
2. Glenn shunt 
3. PA banding 
4. LMBTS 
5. RMBTS 
6. TCPC 
7. Other. Please describe:  
______________________ (text)
 
Definitive surgery? 
1. Yes 
2. No 
 
If yes, 
1. Aortic valve replacement 
2. Arterial switch procedure 
3. ASD repair 
4. AVSD repair 
5. Coarctation repair 
6. Interrupted aortic arch repair 
7. Mitral valve replacement 
8. PDA ligation 
9. Ross- Konno procedure 
10. TAPVD Repair 
11. Tetralogy of Fallot repair 
12. VSD repair 
13. Other. Please describe 
_______________________ (text) 
 
Bypass time:       _________ (Minutes) 
 
Cross-clamp time:      __________ (Minutes) 
 
Other incidental surgeries?  
1. None 
2. Cleft palate repair 
3. Diaphragmatic hernia repair 
4. Diaphragm plication 
5. Percutaneous gastrostomy  
6. Other. Please describe. _____________________________ (Text) 
7. Unknown/Missing      
 
5. COMPLICATIONS 
Primary post-operative complications  
1. None 
2. Arrhythmia 
3. Bleeding 
4. Cardiac failure 
5. Chylothorax 
6. Diaphragmatic Paralysis 
7. Infection 
8. Pleural effusion 
9. Pericardial effusion 
10. Pulmonary hypertensive crisis 
11. Seizures 
12. Other: Please describe 
________________________(text) 
 
Residual defects  
1. Yes   2. No 
 
If yes 
1. Requiring further intervention 
Describe____________________________________________________ (text) 
2. No further intervention required 
Describe ___________________________________________________ (text) 
6. DEATH 
1. Yes 
2. No 
 
 
If yes,  
1. Intraoperative Death 
2. Early postoperative mortality 
3. *Late postoperative mortality 
4. Unknown/Missing 
 
Date of death:     ______________ (DD/MM/YYYY) 
 
Cause of Death: 
1. Respiratory failure 
2. Post-operative low cardiac output 
syndrome 
3. Right heart failure 
4. Myocardial infarction 
5. Refractory ventricular 
tachyarrhythmia 
6. Traumatic pericardiocentesis 
7. Other: __________________ (text) 
8. Missing/Unknown                
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7. INPATIENT DAYS 
Number of days in PICU/ICU post-surgery:     _____________ (0 to XX) 
Number of days in hospital:     _____________ (0 to XXX) 
Date of discharge back to Windhoek:    ______________ (DD/MM/YYYY)  
8.  FOLLOW-UP DETAILS 
*Has patient died since returning to Namibia (late mortality)? 
1. Yes  
If yes, 
Date of death      ______________ (DD/MM/YYYY) 
Cause of death if known _________________________________________ (text) 
2. No 
If no, 
Most recent follow up appointment date:   ______________ (DD/MM/YYYY)  
Number of kept follow up appointments since intervention: ____________________ 
Number of expected follow up appointments since intervention: ________________ 
3. Unknown, lost to follow up 
Number of attempts to trace patient: 
1. <5 
2. >5 
Details: ______________________________________________________________ (text) 
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Acronyms and Abbreviations 
 
 
ARF Acute rheumatic fever 
ASAP Awareness Surveillance Advocacy Prevention 
CBMH Chris Barnard Memorial Hospital 
CCF Congestive cardiac failure 
CHD Congenital Heart Disease 
CI Confidence interval 
CRF Case report forms 
GAS Group A Streptococcus 
GDP Gross Domestic Product 
ICU Intensive Care Unit 
MDGs Millennium Development Goals 
MHSS   Ministry of Health and Social Services 
NCHP Namibia Children Heart Project 
PASCAR Pan African Society of Cardiology 
PPP Private Public Partnership 
RCWMCH Red Cross War Memorial Children’s Hospital 
REMEDY The Global Rheumatic Heart Disease Registry 
RHD Rheumatic Heart Disease 
RHDGen RHD Genetic Consortium 
SACH Save a Child’s Heart 
UN United Nations 
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WHF World Heart Federation 
WHO World Health Organisation 
 
 
 
1 Purpose of the study 
 
Congenital heart disease (CHD) is the most common birth defect globally and is 
associated with significant morbidity and mortality1,2.   Rheumatic heart disease 
(RHD), the sequel to acute rheumatic fever (ARF) and Group A streptococcus (GAS), 
is the most commonly acquired heart disease in developing countries 3.  This 
combination results in a high burden of childhood heart diseases in African countries 
such as Namibia 4.  
 
Namibia has a vast land area of 820 km2 but a relatively sparse population of just over 
2.3 million people. It is categorized as an upper- middle income country with a Gross 
Domestic Product (GDP) approximated at USD 12,99 billion and a GDP per capita of 
USD 4677 as reported by the World Bank in 2014. However there is an uneven income 
distribution as measured by a high Gini co-efficient of 0,67, just below South Africa 
and Brazil 5. Prior to 2009 there were no dedicated paediatric cardiac services in 
Namibia and every child with a cardiac condition from an indigent family dependent 
on state health services suffered the inevitable consequences of their heart disease. 
The United Nations (UN) millennium development goals (MDGs) did not include heart 
disease in children. Resources were focused on combating infectious diseases even 
though CHD is a significant contributor to under-5 mortality globally. Namibia was no 
exception to this unfortunate reality and children with heart disease continued to suffer 
neglect. A paediatric cardiac service was thus established in Namibia in 2009 with a 
step-wise introduction of clinical services, a catheterisation laboratory and finally a 
limited surgical program. Between 2009 and 2015, over 200 patients were sent to 
South Africa for cardiac intervention and/or surgery. 
 
This study aims to describe the clinical characteristics of the patients referred to South 
Africa for further intervention, to quantify morbidity and mortality and to identify 
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prognostic indicators for perioperative and postoperative morbidity and mortality. 
Finally, we will document and describe the follow-up patterns of these patients upon 
return to Namibia. 
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Literature review 
 
2.1. Background 
 
Prior to 2010, there was no dedicated cardiac service in Namibia. Without the ability 
to diagnose or treat heart disease, there was a general lack of awareness about the 
diseases. Care was provided as part of general paediatric practice with patients 
(mostly with rheumatic heart disease) occasionally referred for surgery to Kenyatta 
National Hospital in Kenya. Surgical outcomes of this programme were poor with little 
effective postoperative care. A visiting cardiothoracic surgeon from South Africa, who 
mostly catered to the adult population, also provided sporadic services. This was a 
period of uncertainty for children both with congenital and acquired heart disease. 
 
The Ministry of Health and Social Services (MHSS) inaugurated the cardiac service at 
Windhoek Central Hospital on 5 August 2008. Professional and technical support was 
provided by cardiologists and surgeons from the Department of Cardiothoracic 
Surgery at the University of Cape Town (Red Cross War Memorial Children’s Hospital 
and Groote Schuur Hospital). In one week, operations were performed on nine 
patients with rheumatic heart disease aged 9-28 years. However, despite considerable 
media attention, this programme was not sustained and with no resident paediatric or 
adult cardiologist in the country there followed a return to the status quo of non-
delivery.  
    
2.2 Initiating the service  
 
The first paediatric cardiologist started working in Namibia as a visiting specialist with 
monthly visits to Windhoek Central Hospital from 2007, eventually establishing a 
regular consultancy service but without any associated surgical services. The Namibia 
Children Heart Project (NCHP) was a collective effort of a cardio-thoracic surgeon and 
a paediatric cardiologist to develop a paediatric cardiac service and initiate cardiac 
surgery. Initially this only entailed a weekly outpatient clinic at Windhoek Central 
Hospital (WCH) but soon after, a weekly dedicated RHD clinic was introduced. 
Outreach clinics were introduced at Rundu and Oshakati state hospitals. The first 
paediatric cardiac catheterization was performed at Windhoek Central Hospital on 18 
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October 2010. In 2011 limited cardiac surgery was started at the hospital for children 
over 20 kgs. The NCHP was facilitated by a local paediatrician and supported by local 
services. A Namibian businessman and philanthropist who funded surgeries for nine 
children at the Panorama Mediclinic in Cape Town initially provided finance. 
Thereafter a public-private partnership (PPP) was brokered between MHSS and the 
Netcare Christiaan Barnard Memorial Hospital (CBMH) in Cape Town where the 
surgeries were performed. 
 
Currently, patients are screened and on appropriate merits (weight over 20 kg and 
non-complex disease as defined using risk stratification scores) are referred for 
surgery in Windhoek. The patients remaining, primarily infants, children and those with 
complex disease are referred to CBMH for interventions. These patients are carefully 
selected based on urgency, prognosis and amenability to surgery. To date, more than 
200 children have been referred to CBMH in Cape Town. The number of referrals is 
ultimately dependent on budgetary resources and space within the busy surgical 
programme at CBMH. Patients are evaluated further at CBMH and a final decision 
made regarding suitability for surgery or intervention. 
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Fig 1. Map of Namibia (taken from www.places.co.za.) Windhoek Central Hospital is 
in the most central region, whereas Rundu and Oshakati Hospitals are situated far 
north. 
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2.3. Capacity building  
 
A comprehensive paediatric cardiac service requires a breadth of clinical and nursing 
skills as well as cardiac anaesthetists, intensivists and technologists. An anaesthetist 
and a technologist were recruited in 2010. The founding members of the team also 
conducted teaching modules for the cardiac unit and paediatricians. One nurse 
received training in paediatric cardiac intensive care at Red Cross War Memorial 
Children’s Hospital (RCWMCH). Medical officers attached to paediatric cardiology 
service have been taught fundamentals of RHD and CHD with one attached to 
RCWMCH as a medical officer for 6 months before returning to the Namibian team in 
late 2009. Subsequently, this medical officer completed 4 years of paediatric training 
and obtained a fellowship (FC Paed) from the College of Medicine of South Africa and 
is now a post-graduate fellow in paediatric cardiology at the RCWMCH.  
Continued growth and ensuring sustainability of the service however requires several 
elements to be in place. These include:  
• Human resource development (e.g. there is currently no dedicated paediatric 
intensivists or paediatric cardiac surgeon in the country)  
• Robust research programmes on congenital and acquired heart diseases 
• Postgraduate training programme within the country.  
 
Currently Namibia is a key site for several international research collaborations around 
RHD - the global rheumatic heart disease registry (REMEDY study) 6, the Africa 
Rheumatic Heart Disease Genetic consortium (RHDGen) and INVICTUS trials. 
 
2.4. Paediatric Cardiac Services in Africa 
 
The prevalence of CHD is 8 - 13 per 1000 live births with Asia reporting the highest 
prevalence 7. This variability is explained in part by genetic, socio-economic and 
environmental/epigenetic factors. The high prevalence of ARF/RHD compounds the 
burden of heart disease in children in developing countries 8. There are little robust 
data concerning the prevalence of CHD or acquired heart disease in Namibia.  
 
There is increasing realisation that the lack of paediatric cardiac services results in a 
high number of preventable deaths and significant morbidity. In industrialized 
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countries, the need to create and fund paediatric units is related to national need. Less 
well-resourced countries however, struggle to create and fund paediatric units relative 
and children with heart disease continue to be neglected. A panel convened by the 
World Health Organisation (WHO) to advise on optimal resources for paediatric 
cardiac services recommended that a centre should be able to perform 300-500 
operations annually for populations of 2 million people. Developing countries need at 
least one centre per 1 million people 9.  Africa faces significant challenges in 
addressing the needs of children with cardiac lesions amenable to operations or 
interventions because of the lack of resources in both specialized personnel and 
funding 10. As a result, there is premature mortality and a higher rate of late 
presentation, rendering these patients as inoperable or at risk of substantial post-
operative morbidity and mortality11. 
 
South Africa, Egypt and Sudan were the first three countries to perform open-heart 
surgeries in adult and paediatric populations and still have the largest programmes on 
the continent 4. These are also the only three countries offering paediatric training 
programmes for both paediatric cardiologists and cardiac surgeons 12.   
 
Many African countries have collaborations with centres in the United States, Europe 
and Asia 11,13,14 where visits are facilitated by humanitarian non-governmental 
organizations. In most cases these have not resulted in the development of local 
sustainable services. Cardiac operations are often conducted during planned surgical 
visits; local teams conduct screening operations in advance of the visit15. Capacity 
building in the form of training is encouraged during these visits to enable the 
development of local sustainable programmes.  
In East Africa, Tanzania has strong collaborations with India and Israel. Recently a 
specialized cardiac team from Israel (through the  Medical Centre’s “Save a Child’s 
Heart” organization) performed more than 20 operations on children with congenital 
heart disease in Tanzania. Kenya has a semi-independent service for children.  They 
have facilities with resident cardiac surgeons performing open-heart surgery.  
Collateral agreements are in place with the UK, India and Israel.  The latter have 
trained the bulk of the workforce in that country.  Children’s Heartlink, a non-
governmental organization had previously worked with Nairobi Hospital in Nairobi, 
Kenya 16. 
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In West and Central Africa, Nigeria, Ghana and Ivory Coast are performing limited 
heart surgery with the help of visiting foreign surgeons too. Sudan has the Salam 
Centre for Cardiac Surgery run by the Italian humanitarian organisation “Emergency.”  
Procedures are performed mostly on a pro bono basis. These programmes have 
largely replaced the previous method of sending individual patients abroad for 
surgery17,18. 
 
In Southern Africa, Zambia has a similar programme where only complex patients 
requiring cardiopulmonary bypass are referred to South Africa or India. A local 
cardiologist provides follow-up. The local Zambian team can provide non-
cardiopulmonary bypass surgery and transthoracic echocardiography. South Africa 
boasts a self-sufficient service in certain centres but still only offers care to 60% of 
children needing surgery in the public sector. The Walter Sisulu Heart Foundation in 
South Africa previously contributed to capacity building by training surgeons from 
other African countries with the intent of establishing centres in their own countries 19. 
Two Namibian and one Zambian cardiothoracic surgeons successfully completed 
training through this initiative. Collaborations through the Pan-African Society of 
Cardiology (PASCAR) are currently underway to ensure that more African surgeons 
and cardiologists receive training20. 
 
In 2002 Children’s HeartLink briefly supported a programme for training critical care 
nurses at RCWMCH in Cape Town, South Africa. This non-governmental organization 
supports partner hospitals with a more sustainable development model in six non-
African countries: Brazil, China, India, Malaysia, Ukraine and Vietnam. The main goal 
of Children’s HeartLink’s program is to build upon the foundation and strengths of any 
pre-existing paediatric cardiac programmes. By delivering targeted, focused support 
to an existing program, Children’s HeartLink accelerates the learning and 
development curve. However, in Sub-Saharan Africa there are very few paediatric 
cardiac programmes with dedicated paediatric specialists who could benefit from their 
current delivery model 21.  Children’s HeartLink is aware of the tremendous need in 
Africa and the organisation is currently exploring some collaborative approaches with 
other organisations, as well as the possibility of developing their own alternative 
approaches, which may enable additional assistance in this region.  
 66 
 
The ASAP (Advocacy, Surveillance, Awareness, Prevention) programme was 
developed for the prevention and control of rheumatic fever and rheumatic heart 
disease by African experts at the “All African” meeting on RHD in 2005 22.  RHD is one 
of the top three aetiological factors of acute heart failure in the younger population of 
sub-Saharan Africa 23. As with CHD, there are limited data on mortality related to RHD. 
In one study conducted in rural Ethiopia, the mortality rate related to untreated 
rheumatic heart disease reached 12,5 % 24.  The Global Registry of Rheumatic Heart 
Disease (REMEDY) is a collaboration between of 12 African countries, India and 
Yemen including Namibia that used a hospital-based registry aimed to prospectively 
describe demographic and patient characteristics, prevailing treatment patterns and 
major outcome patterns in order to provide information to respective governments for 
formulating policy and guidelines for the control and treatment of RHD 25. 
 
In general, these curative and preventative efforts for children with heart disease have 
little governmental commitment in developing countries in Africa. Considering the 
substantial support from the MHSS, Namibia presents a unique model with a funded 
national programme and budget to the NCHP. 
 
3 Aims and objectives 
 
3.1 Aims 
 
This study’s four major aims are: 
1) To describe the clinical characteristics of the patients referred from Namibia 
to South Africa for surgery or intervention  
2) To quantify morbidity and mortality  
3) To identify prognostic indicators for perioperative morbidity and mortality.  
4) To document the follow-up patterns of these patients upon return to Namibia. 
 
3.2. Study objectives 
 
• To describe baseline characteristics, diagnoses, interventions and outcomes 
of the patients who were referred to and received cardiac services at CBMH. 
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• To quantify morbidity and mortality in this cohort 
• To assess how the age at presentation, age at surgery and complexity/high 
risk stratification scores affect the overall outcome as measured by morbidity 
and mortality  
• To describe and quantify the number of patients who were deemed 
inappropriate candidates for surgery at CBMH because of late presentation 
and/or complexity. 
• To document post-intervention, follow up patterns.  
 
 
4 Methods 
4.1 Study design 
 
This is a retrospective study of a cohort of 200 patients with congenital and acquired 
heart disease recruited in Namibia and referred from WCH to CBMH for surgery and/or 
intervention between January 2009 and December 2015.  
4.2 Inclusion criteria 
 
• All patients sent to CBMH in Cape Town for cardiac interventions between 1 
January 2009 and 31 December 2015.  
4.3 Exclusion criteria 
 
• Patients outside the said time frame  
• Patients whose surgeries were performed at WCH in Windhoek. 
 
5 Data sources  
 
The data sources will be the patients' registries at WCH and CBMH, the cardiologist’s 
case notes and the cardiothoracic surgeons’ surgical notes. Variables to be analysed 
include; demographics, diagnosis, catheterization and surgery details, morbidity and 
mortality as well as follow up details.  
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A standardised data collection form capturing all relevant demographic, clinical, 
catheterisation and surgery details, outcomes and follow- up patterns from medical 
records will be used (Appendix 1).  
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6 Data management and statistical analysis 
 
The data collected will be captured using Microsoft excel, coded accordingly and 
analysed using STATA 14.0.  Continuous variables will be expressed as means with 
standard deviations, or medians with interquartile ranges as appropriate. Categorical 
variables will be expressed as frequencies and percentages. Linear regression models 
will assess the relationship between the variables. Cox regression models will be used 
to assess the risk of appropriate variables with survival. 
 
7 Ethics  
 
Ethical approval has been obtained from the Ministry of Health and Social Services 
(MHSS) in Namibia with a waiver of consent for this study from patients. As this is a 
retrospective review, we are requesting a waiver of consent from the University of 
Cape Town Human Ethics Committee. Patients' identities will be fully protected by 
assigning a Subject ID number to be used on data collection forms in lieu of the 
patients’ names. A key linking the names to the Subject IDs will be maintained in a 
secure manner by the trainee investigator. Raw data will not be shared beyond the 
research team members.  
 
8 Duration of the project 
 
Data collection, analysis and consolidation will take an estimated 3-6 months. We 
anticipate completing the project within 6-9 months. 
  
 70 
 
9 Funding budget 
 
An operational budget of R9100 will be required. A cost breakdown is shown in Table 
1. 
Table 1. Budget 
 
Calls to Namibia to ascertain follow-up 
status of patients 
R1000 
Photocopies of surgical records R1000 
HDD 2T R1500 
Printing  R1000 
Stata 14.0 license  R2500 (for student license) 
Open Access Journal Fees (CVJA) R1500  
Good Clinical Practice Course (Creede) R600 
 
 
10 Outputs/Dissemination of results 
 
1. This research is in partial fulfilment of the degree of M.Phil. The final publication will 
be submitted both for the thesis and for publication in a peer-reviewed journal.  
2. Information regarding the outcomes of the study will be shared with the Namibian 
Ministry of Health and Social Services, Christian Barnard Hospital, Harold and Ethel 
Pupkewitz Heart Foundation and all local intermediate/secondary hospitals in the 
referral regions. 
3. Outcomes of the study as an abstract will also be presented at national and 
international cardiology congresses. 
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11 Proposed graphs/Tables 
Table 1. Demographic data 
Age at presentation  
Sex  
Region in Namibia  
 
Table 2. Diagnosis 
Primary diagnosis  
Secondary diagnosis  
Additional associations  
 
Table 3. Left to right shunts 
Atrial septal defect  
Atrio-ventricular septal defect   
Ventricular septal defect  
Patent ductus arteriosus   
 
Table 4. Right ventricular outflow tract obstructions 
Tetralogy of Fallot  
Double outlet right ventricle-
Tetralogy of Fallot type 
 
Tetralogy of Fallot with pulmonary 
atresia  
 
Pulmonary stenosis  
Double chambered right ventricle  
 
 
Table 5. Left ventricular outflow tract obstructions 
Coarctation of Aorta  
Interrupted aortic arch   
Subaortic stenosis  
Valvar aortic stenosis  
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Table 6. Univentricular pathology 
Tricuspid atresia   
Double inlet left ventricle  
Double outlet right ventricle   
 
Table 7. Congenital mitral valve abnormalities 
Mitral stenosis  
Double orifice mitral valve  
Mitral valve prolapse   
 
Table 8. Additional lesions 
 
 
 
Table 9. Acquired Heart Disease 
 
 
 
 
 
Table 10. Clinical findings 
Pulmonary hypertension  
Cardiac failure  
Failure to thrive   
Hypercyanosis  
 
Total anomalous pulmonary venous 
drainage 
 
Partial anomalous pulmonary 
venous drainage 
 
Atrio-ventricular disconcordance  
Ventriculo-arterial disconcordance    
Isomeric atrial appendages  
Other  
Takayasu arteritis  
Rheumatic heart disease  
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Table 11. Catheterisation 
Diagnostic   
Haemodynamic  
Interventional  
 
Table 12. Findings at diagnostic/ haemodynamic catheterisation 
Irreversible PHT  
Complex and inoperable anatomy  
 
Table 13. Interventional catheterisation 
Stent  
Pulmonary balloon valvuloplasty  
Inoue balloon mitral valve 
commissurotomy 
 
PDA device closure  
Secundum ASD device closure  
Radio-frequency (RF) ablation  
 
Table 14. Surgical Intervention and details  
Type of surgery  
Palliative  
Full repair  
 
  
Table 15. Complications  
Arrhythmia  
Bleeding   
Low cardiac output syndrome  
 
Table 16. Mortality and details 
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Intraoperative mortality  
Early postoperative mortality  
Late postoperative mortality  
 
Table 17. Lost to follow-up (n=) 
Diagnosis  
Age  
Region  
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Appendum 4: Diagnosis and procedures codes 
Thesis submission\Diagnostic and procedure codes.xlsx 
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